v3.26.1
Segment Reporting (Summary of Net Revenues by Product) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues $ 171,171 $ 170,528
Finished Pharmaceutical Products Segment    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 171,171 170,528
Finished Pharmaceutical Products Segment | Glucagon    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 9,170 20,843
Finished Pharmaceutical Products Segment | Primatene MIST    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 29,763 29,051
Finished Pharmaceutical Products Segment | BAQSIMI    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 32,434 38,355
Finished Pharmaceutical Products Segment | Epinephrine    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 19,213 18,587
Finished Pharmaceutical Products Segment | Lidocaine    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues 13,460 13,644
Finished Pharmaceutical Products Segment | Other Products    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Revenues $ 67,131 $ 50,048